Keyword: Taltz

A couple of drugmakers are celebrating this week after favorable decisions from England’s cost watchdog.

China's inviting top brands from Lilly, Novartis, GSK and more to go for approval based on foreign clinical trial data.

Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara.

Roche sued Lilly Tuesday, claiming the two-year-old psoriasis med Taltz steps on one of its patents. Thing is, Roche just won that patent this week.

With some new data in hand, Eli Lilly's Taltz looks poised to challenge Novartis' Cosentyx in a third indication.

As the psoriatic arthritis field heats up, Novartis has added some new data to its Cosentyx label it hopes can stretch out the drug’s lead.

Lilly analysts worry growth could suffer if it doesn't win a nod for both baricitinib doses—and an FDA panel shot down one of them Monday.

After a bruising two-day play-in, Taltz and Nerlyx are among the victors in our first round of this year’s drug name tournament challenge.

In December, Eli Lilly’s Taltz got a go-ahead to take on rival Cosentyx from Novartis in its second indication. But it’s not stopping there.

Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018 guidance.